Table 2.
Proportion of patients with group A COVID-19 symptoms, intent-to-treat population.
| Placebo | Hesperidin | All | OR (95% CI)a | p valuea | |
|---|---|---|---|---|---|
| Day 1 | N = 107 | N = 104 | N = 211 | ||
| No | 12 (11.2%) | 12 (11.5%) | 24 (11.4%) | ||
| Yesb | 95 (88.8%) | 92 (88.5%) | 187 (88.6%) | 0.97 (0.41; 2.28) | 0.9413 |
|
| |||||
| Day 3 | N = 103 | N = 102 | N = 205 | ||
| No | 13 (12.6%) | 9 (8.8%) | 22 (10.7%) | ||
| Yesb | 90 (87.4%) | 93 (91.2%) | 183 (89.3%) | 1.49 (0.60; 3.69) | 0.3849 |
|
| |||||
| Day 7 | N = 101 | N = 91 | N = 192 | ||
| No | 25 (24.8%) | 17 (18.7%) | 42 (21.9%) | ||
| Yesb | 76 (75.2%) | 74 (81.3%) | 150 (78.1%) | 1.43 (0.71; 2.88) | 0.3139 |
|
| |||||
| Day 10 | N = 99 | N = 90 | N = 189 | ||
| No | 39 (39.4%) | 32 (35.6%) | 71 (37.6%) | ||
| Yesb | 60 (60.6%) | 58 (64.4%) | 118 (62.4%) | 1.18 (0.65; 2.14) | 0.5886 |
|
| |||||
| Day 14 | N = 94 | N = 79 | N = 173 | ||
| No | 39 (41.5%) | 40 (50.6%) | 79 (45.7%) | ||
| Yesb | 55 (58.5%) | 39 (49.4%) | 94 (54.3%) | 0.69 (0.38; 1.27) | 0.2328 |
aComparison between the placebo group and hesperidin group. Significant when p < 0.05. bSubject has at least one of the group A COVID-19 symptoms: fever, cough, shortness of breath, or anosmia. N represents the number of subjects who completed the daily symptom diary.